Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction.

The Journal of neuroscience : the official journal of the Society for Neuroscience | 2010

Mutations in leucine-rich repeat kinase 2 (LRRK2) are linked to familial as well as sporadic forms of Parkinson's disease (PD), a neurodegenerative disease characterized by dysfunction and degeneration of dopaminergic and other types of neurons. The molecular and cellular mechanisms underlying LRRK2 action remain poorly defined. Here, we show that LRRK2 controls synaptic morphogenesis at the Drosophila neuromuscular junction. Loss of Drosophila LRRK2 results in synaptic overgrowth, whereas overexpression of Drosophila LRRK or human LRRK2 has opposite effects. Alteration of LRRK2 activity also affects neurotransmission. LRRK2 exerts its effects on synaptic morphology by interacting with distinct downstream effectors at the presynaptic and postsynaptic compartments. At the postsynapse, LRRK2 interacts with the previously characterized substrate 4E-BP, an inhibitor of protein synthesis. At the presynapse, LRRK2 phosphorylates and negatively regulates the microtubule (MT)-binding protein Futsch. These results implicate synaptic dysfunction caused by deregulated protein synthesis and aberrant MT dynamics in LRRK2 pathogenesis and offer a new paradigm for understanding and ultimately treating PD.

Pubmed ID: 21159966 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Associated grants

  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR054926-02
  • Agency: NIAMS NIH HHS, United States
    Id: R01AR054926
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH080378-02
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH080378
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH080378-01A2
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR054926-01A2
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR054926-05
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR054926
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR054926-04
  • Agency: NIAMS NIH HHS, United States
    Id: R01 AR054926-03
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH080378-03
  • Agency: NIMH NIH HHS, United States
    Id: R01MH080378

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.